Zenas BioPharma Prices $300M Concurrent Offerings Of $200M 2.50% Convertible Senior Notes Due 2032 And 5M Shares At $20 To Fund Obexelimab Launch

Benzinga Newsdesk www.benzinga.com Neutral 90.3%